The following excerpt is from John Stone at The Defender:
UK Data Show 402 Reports of Deaths Following COVID Vaccines
Government data show that, compared with the Pfizer vaccine, there have been 43% more reports of injuries related to the Oxford-AstraZeneca vaccine in the UK, including 77% more adverse events and 25% more deaths — but no red flags from UK regulators.
Between Dec. 9, 2020 (when the first COVID vaccine was administered in the UK) and Feb. 14, 2021, 402 deaths following COVID vaccines have been reported to YellowCard, the UK government’s system for reporting side effects to COVID-related medicines, vaccines, devices, and defective or falsified products.
Britain’s regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), runs YellowCard, which is the nearest British equivalent to the Vaccine Adverse Events Reporting System or VAERS in the U.S.
So far, only the Pfizer-BioNTech and Oxford-AstraZeneca vaccines have been administered in the UK. The Pfizer vaccine was deployed during the second week of December 2020, and Oxford-AstraZeneca at the beginning of January. (Moderna’s COVID vaccine is approved for emergency use in the UK, but the country has not as of yet obtained any vaccines from the company).
The MHRA has expressed no concern about the number of reports of adverse events connected with these new products, even failing to note how much worse the Oxford product has performed in comparison to the Pfizer vaccine.
Similarly, the accumulation of hundreds of deaths has failed to register a flicker of concern from them.
In January, the deaths of 23 frail elderly in Norway made international news — and raised questions about whether we should even be vaccinating people who are already near death. While it’s true that thousands of frail elderly people inevitably die every week, the lack of evidence of an active attempt to find out what is going on in individual cases is troubling.
The MHRA responded to the Norwegian report by saying “it did not currently anticipate any specific concerns,” a highly prejudicial statement. At the time The BMJ (formerly the British Medical Journal) permitted a short on-line response from me under the title “Is the MHRA up to it?”: Read more at The Defender.